Forgot details?

Return to login form

Advances In Averting Cardiovascular Anomalies To Diabetes

DRUG REVIEW, 4 November 2009
doi: 10.5083/ejcm.20424884.05 , Cite or Link Using DOI
Creating a Digital Object Identifier Link

A digital object identifier (DOI) can be used to cite and link to electronic documents. A DOI is guaranteed never to change, so you can use it to link permanently to electronic documents.

To find a document using a DOI

  1. Copy the DOI of the document you want to open.
    The correct format for citing a DOI is as follows: doi:10.1016/S0140-6736(08)61345-8
  2. Open the following DOI site in your browser:
    dx.doi.org
  3. Enter the entire DOI citation in the text box provided, and then click Go.
    The document that matches the DOI citation will display in your browser window.

The DOI scheme is administered by the International DOI Foundation. Many of the world's leading publishers have come together to build a DOI-based document linking scheme known as CrossRef.

Abdalla M. El-Mowafy

Cardiovascular disease (CVD) is a prime killer in patients with diabetes, but improvements in fighting CVD have not tangibly been seen in patients with diabetes. This can be attributed to multiple pathophysiological triggers of CVD in diabetes, shortcomings with current CV-treatments or adverse reactions to drugs used to restore normoglycaemia (mainly hypoglycaemia). Therefore, experts and regulatory authorities have suggested that new drugs for diabetes will need to demonstrate cardiovascular safety before approval, either by not showing a signal for cardiovascular risk or through long-term clinical trials. On the other hand, the role of tight glycaemic control in reducing cardiovascular events and mortality in diabetes has not yet been firmly established, as some recent clinical trials have yielded unexpected outcomes. Thus, recently, many clinical studies have aimed to reveal the molecular underpinnings linking diabetes with cardiovascular disease in most relevant tissues, hoping to develop new strategies against diabetes-evoked CVD.

Correspondence to:
Abdalla El-Mowafy, Prof. of Biochemistry /Therapeutics, Egypt. Univ. Promotions’ Committee/Biochemistry Faculty of Pharmacy, Mansoura University 35512, Mansoura, Egypt. aelmowafy@yahoo.com

Keywords:

CVD in diabetes, new drugs for diabetes, diabetes-evoked CVD